

Citation:

Aldrich, L and Ispoglou, T and Prokopidis, K and Alqallaf, J and Wilson, O and Stavropoulos-Kalinoglou, A (2025) Acute Sarcopenia: systematic review and meta-analysis on its incidence and muscle parameter shifts during hospitalisation. Journal of Cachexia, Sarcopenia and Muscle, 16 (1). pp. 1-21. ISSN 2190-5991 DOI: https://doi.org/10.1002/jcsm.13662

Link to Leeds Beckett Repository record: https://eprints.leedsbeckett.ac.uk/id/eprint/11476/

Document Version: Article (Published Version)

Creative Commons: Attribution 4.0

© 2025 The Author(s)

The aim of the Leeds Beckett Repository is to provide open access to our research, as required by funder policies and permitted by publishers and copyright law.

The Leeds Beckett repository holds a wide range of publications, each of which has been checked for copyright and the relevant embargo period has been applied by the Research Services team.

We operate on a standard take-down policy. If you are the author or publisher of an output and you would like it removed from the repository, please contact us and we will investigate on a case-by-case basis.

Each thesis in the repository has been cleared where necessary by the author for third party copyright. If you would like a thesis to be removed from the repository or believe there is an issue with copyright, please contact us on openaccess@leedsbeckett.ac.uk and we will investigate on a case-by-case basis.

REVIEW OPEN ACCESS

# Acute Sarcopenia: Systematic Review and Meta-Analysis on Its Incidence and Muscle Parameter Shifts During Hospitalisation

<sup>1</sup>Carnegie School of Sport, Leeds Beckett University, Headingley Campus, Leeds, UK | <sup>2</sup>Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK

Correspondence: Luke Aldrich (l.aldrich@leedsbeckett.ac.uk)

Received: 28 January 2024 | Revised: 22 October 2024 | Accepted: 31 October 2024

Funding: This research was funded by Leeds Beckett University.

Keywords: atrophy | cachexia | disuse | wasting | weakness

## ABSTRACT

**Background:** Acute sarcopenia is sarcopenia lasting less than 6 months, typically following acute illness or injury. It may impact patient recovery and quality of life, advancing to chronic sarcopenia. However, its development and assessment remain poorly understood, particularly during hospitalisation. This systematic review aimed to elucidate the incidence of acute sarcopenia and examine changes in muscle parameters during hospitalisation.

**Methods:** Eighty-eight papers were included in the narrative synthesis; 33 provided data for meta-analyses on the effects of hospitalisation on handgrip strength (HGS), rectus femoris cross-sectional area (RFCSA) and various muscle function tests. Meta-regressions were performed for length of hospital stay (LoS) and age for all meta-analyses; sex was also considered for HGS. **Results:** Acute sarcopenia development was assessed in four studies with a pooled incidence of 18% during hospitalisation. Incidence was highest among trauma patients in intensive care (59%), whereas it was lower among medical and surgical patients (15%–20%). Time of development ranged from 4 to 44 days. HGS remained stable during hospitalisation (SMD=0.05, 95% CI=-0.18:0.28, p=0.67) as did knee extensor strength. LoS affected HGS performance ( $\theta=0.04$ , 95% CI=-0.001:0.09, p=0.045) but age (p=0.903) and sex (p=0.434) did not. RFCSA, reduced by 16.5% over 3–21 days (SMD=-0.67, 95% CI=-0.92:-0.43, p<0.001); LoS or time between scans did significantly predict the reduction ( $\theta=-0.04$ , 95% CI=-0.077:-0.011, p=0.012). Indices of muscle quality also reduced. Muscle function improved when assessed by the short physical performance battery (SMD=0.86, 95% CI=-0.03:1.69, p=0.046); there was no change in 6-min walk (p=0.22), timed up-and-go (p=0.46) or gait speed tests (p=0.98). The only significant predictor of timed up-and-go performance was age ( $\theta=-0.11$ , 95% CI=-0.018:-0.005, p=0.009).

**Conclusions:** Assessment and understanding of acute sarcopenia in clinical settings are limited. Incidence varies between clinical conditions, and muscle parameters are affected differently. HGS and muscle function tests may not be sensitive enough to identify acute changes during hospitalisation. Currently, muscle health deterioration may be underdiagnosed impacting recovery, quality of life and overall health following hospitalisation. Further evaluation is necessary to determine the suitability of existing diagnostic criteria of acute sarcopenia. Muscle mass and quality indices might need to become the primary determinants for muscle health assessment in hospitalised populations.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

<sup>© 2025</sup> The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

# 1 | Background + Introduction

Acute sarcopenia refers to the rapid deterioration of muscle health, developing secondary to a medical event, such as an illness or injury [1]. In intensive care units (ICUs), muscle wasting may be associated with prolonged length of stay and increased mortality [2–4]. After discharge, acute sarcopenia may predispose people to developing chronic sarcopenia, the long-term progressive age-related decline of muscle health. Chronic sarcopenia is known to compromise quality of life, independence and overall health as well as increase the risk of other comorbidities, frailty and mortality [5–8]. Therefore, accurate identification of acute sarcopenia is of paramount importance.

An attempt to outline the diagnosis and characteristics of acute sarcopenia was made by the European Working Group on Sarcopenia in Older People (EWGSOP2) [1]. Acute and chronic sarcopenia share common diagnostic criteria within muscle health, such as strength, mass, quality and function, but acute sarcopenia lasts 6 months or less [1]. However, it is unclear if all aspects of muscle health deteriorate at the same rate and if some are more sensitive to acute changes.

Further, the diagnosis of sarcopenia is based on muscle parameters reaching specific thresholds rather than a rate of change or magnitude of reduction. For example, a male patient's handgrip strength (HGS) may decrease from 50 kg at hospital admission to 30 kg at discharge, a 40% reduction. However, this does not meet the EWGSOP2 threshold of < 27 kg, which is necessary to classify as probable sarcopenia risk [1]. These thresholds, which are based on normative data from studies involving predominantly healthy older adults [1, 9], may not accurately reflect the risk of severity of sarcopenia in diverse, clinically distinct populations.

This reliance on static thresholds fails to capture the nuances of acute muscle health deterioration in people experiencing medical emergencies, which can impede effective management and treatment [10]. Acute sarcopenia may develop very rapidly; Welch et al. [11] suggested that muscle health may deteriorate within 28 days of an illness or injury. Indeed, in the first week of ICU stay, people may experience a daily loss of 2% in muscle mass amounting to > 10% losses within a week [12].

The precise mechanisms underpinning acute sarcopenia are unclear; however, the extent of muscle mass reduction in ICU patients is more pronounced than in healthy individuals exposed to bed rest and limb suspension [13]. This suggests that there is an interplay between muscle protein synthesis and degradation [14], inflammation [15], hormonal changes and mitochondrial dysfunction [2] in acute sarcopenia development and muscle atrophy in a clinical setting. Inevitably, this requires a refined approach to sarcopenia diagnosis and management in this setting.

Acute sarcopenia is often associated with chronic diseases and symptoms such as low-grade inflammation and hormonal imbalances, which induce a catabolic state within the muscle [2]. Other causes could include immobilisation from injury, leading to muscle degradation through reduced mechanical loading [13, 14], mitochondrial dysfunction and insulin resistance [16, 17]. These molecular changes ultimately lead to the accelerated onset of more obvious morphological and physical changes experienced during hospitalisation, that is, reduced muscle mass, strength, quality and function.

Understanding the onset of acute sarcopenia in different hospitalised patients is an urgent priority. By achieving this, we can develop accurate definitions and criteria, which in turn will inform the design and implementation of effective strategies to mitigate the condition for individuals subjected to hospitalisation. With these considerations in mind, the objectives of this systematic review and meta-analysis are to

- i. Determine the incidence of acute sarcopenia development in hospitalised patients,
- ii. Understand the changes that occur to different muscle parameters that are involved in sarcopenia assessments in specific hospitalised patients.

# 2 | Methods

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria [18]. The review received PROSPERO accreditation with the complete protocol for this research available for viewing (CRD42022329996).

## 2.1 | Data Sources and Searches

An exhaustive search strategy (supplementary material) was devised to identify studies that investigated or observed parameters of acute sarcopenia resulting from illness or injury in populations with or recovering from disease. Studies only included hospitalised populations.

Search terms were applied to both title and abstract fields using the following databases: PubMed, Cochrane Library, Embase, CINAHL, APA PsycInfo and SPORTDiscus. Filters for 'Humans', 'English' and 'Adults' were applied. No filters were applied to publication date. The results were exported to EndNote 20 (Clarivate) to aid in organising and filing. Only primary studies were included in the synthesis. Pertinent reviews in the field, identified through the search strategy, had their reference lists reviewed for potential eligibility of studies not captured by the search strategy.

# 2.2 | Inclusion and Exclusion Criteria

Inclusion criteria were as follows: patients with or recovering from disease in hospital, patients with acute illness or injury requiring hospitalisation, assessments of muscle strength, mass, quality or function at a minimum of two different time points during hospitalisation, intervention studies with a relevant control group and observational cohort studies.

Exclusion criteria were as follows: adolescents or children (aged < 18 years), athletic populations and injuries, only one time point assessment of muscle parameters, cohorts with preexisting sarcopenia at the first/baseline assessment or where acute and chronic sarcopenia could not be differentiated, first/ baseline assessment obtained > 4 days since hospital admission and cohorts with cancer or similar condition requiring chemotherapy treatment.

For studies assessing sarcopenia, we included all with any recognised or validated definition or assessment methods [i.e., EWGSOP1, EWGSOP2, Foundation for the National Institutes of Health, Asian Working Group for Sarcopenia (AWGS) 1, AWGS2, International Working Group for Sarcopenia (IWGS), Baumgartner, Mourtzakis, Morley, Sarcopenia Definitions and Outcomes Consortium (SDOC) and Delmonico]. Rapid sarcopenia development was determined based on the diagnosis of sarcopenia within current definitions, but within the 6-month period outlined by the EWGSOP2 [1]. Studies that measured HGS, knee extensor strength (KES), muscle mass, quality or function were also included.

# 2.3 | Data Extraction and Quality Assessment

Two investigators (LA and KP) independently evaluated titles and abstracts of all initial results to identify studies for full-text review. In case of uncertainty, the article underwent a full-text review for a comprehensive understanding. The same investigators independently conducted full-text reviews. Any disagreements were resolved through discussion and if consensus could not be reached, a third reviewer (ASK) was consulted. The screening process is outlined in Figure 1.

Data extraction was conducted using the Cochrane tool for data extraction (The Cochrane Collaboration, v.3) with additional

relevant criteria added. Key criteria included study information, methodological details and sarcopenia muscle parameters. Extraction for all studies was performed in duplicate (LA and KP).

Studies were assessed for bias (LA and KP) using the National Heart, Lung and Blood Institute tools appropriate for each study design (National Heart, Lung and Blood Institute, Study Quality Assessment Tools, NHLBI, 2021. *Accessed: 16.01.2023*).

## 2.4 | Data Synthesis and Analysis

A narrative synthesis was performed with tabular synthesis where appropriate. To interpret results, data were categorised based on muscular parameters assessed, assessment tools used, hospitalised patient groups (e.g., COVID-19 and trauma) and their exposures (e.g., ICU and medical ward).

Mean and standard deviations (SD) and 95% confidence intervals (CI) are reported where appropriate. Where sufficient data were available, that is, when a minimum of three studies per variable provided clear data for admission and discharge/follow-up during hospitalisation, meta-analyses were conducted for quantitative analysis.

Statistical analyses were performed using package metafor in R version 4.2 (R Foundation for Statistical Computing, Vienna, Austria). A random-effects model was used to determine overall effect size using preobservation to postobservation values to calculate standardised mean difference (SMD) and 95% confidence intervals (CIs) [19].



FIGURE 1 | Flow diagram outlining the identification and screening process according to PRISMA [18] guidelines.

CIs and test statistics were calculated via a *t*-distribution using the Hartung–Knapp–Sidik–Jonkman approach [20]. Effect sizes were interpreted as trivial (< 0.2), small (0.20–0.49), moderate (0.50–0.79) and large (> 0.79), according to Cohen's recommendations [21].

Meta-analysis results are presented in forest plots containing SMD and CIs, significance (*p*-value set at < 0.05) and heterogeneity assessed by the *I*<sup>2</sup> statistic. Heterogeneity was considered unimportant (0%–40%), moderate (30%–60%), substantial (50%–90%) and considerable (75%–100%), according to Cochrane recommendations [22].

Meta-regression analyses were performed to identify predictors of change in SMD, such as the duration of hospital stay and sex. If a meta-analysis included more than one outcome measure from the same study, effect estimates were nested within studies using a multilevel structure [23]. Where meta-analyses were performed with only three studies and there was large heterogeneity, sensitivity analyses were performed by removal of each study to ascertain whether this would affect the model parameters.

## 3 | Results

## 3.1 | Study Inclusion and Risk of Bias

The final searches, conducted on 18.06.2024, yielded 21754 potentially eligible articles. After removal of duplicates, 21694 remained for screening of titles and abstracts. Relevant systematic reviews and meta-analyses were also searched to identify further relevant studies. Utilising rigorous inclusion and exclusion criteria, 294 publications remained for full-text review. Of those, 206 were excluded (Figure 1), leaving 88 articles for synthesis.

Eighty-eight studies included for synthesis involved 9476 patients, from 38 randomised controlled trials (RCTs) and 50 observational cohort studies, whose data were extracted as part of the selection criteria. The specific age range of included patients is unclear; however, the mean and median ages of patients within included studies spanned from 33 to 88 years. All included studies took place in a hospitalised setting with information provided in Table 1. The overall risk of bias for the RCTs and observational cohort studies were low and high, respectively (Tables S1 and S2).

## 3.2 | Acute Sarcopenia Development

Four studies specifically assessed the development of sarcopenia during a period of hospitalisation [28, 54, 71, 102].

In a large cohort study, Martone et al. [71] observed sarcopenia development in 14.7% (58 out of 394) patients over a mean period of  $5.4 \pm 6.7$  days. Sarcopenia was determined according to EWGSOP1 criteria [109]. Over half of these patients also experienced a reduction of more than 10% of muscle mass. Using updated EWGSOP2 criteria [1], another large-scale study identified 19% of a medical cohort developed sarcopenia over 7 days of hospitalisation [28]. Furthermore, Welch et al. [102, 103] reported 20% of their cohort developed sarcopenia, whereas an additional 8% developed probable sarcopenia within an average period of  $7 \pm 2$  days. Only 10% of their cohort showed no reductions in any muscle parameters. Haines et al. [54] identified variable rates of sarcopenia development (8%–59%), over 4–44 days in ICU trauma patients, using abdominal CSA as a determinant of muscle mass and sarcopenia diagnosis.

When pooling the data from these studies together, 126 out of 708 hospitalised patients (18%) developed sarcopenia during a hospital stay ranging from 4 to 44 days.

## 3.3 | Muscle Strength

#### 3.3.1 | Handgrip Strength

Twenty-nine studies assessed changes in HGS during hospitalisation (Table S3). The response of HGS to hospitalisation was variable: Some reported a reduction in HGS [33, 39, 40, 42, 51, 69, 70, 78], whereas others observed an increase [39, 41, 58, 65, 69, 80, 87, 93, 106]. These changes typically occurred within a period of 5–30 days. Six studies found no change in HGS [31, 66, 74, 80, 101, 104].

Furthermore, we conducted a meta-analysis on the studies that provided sufficient data (n=14). There was no significant change in HGS with a trivial effect size (SMD = 0.05, 95% CI = -0.18:0.28, p=0.67; Figure 2). Meta-regression analyses revealed that length of stay was a significant predictor of change for HGS ( $\theta=0.04$ , 95% CI = 0.001:0.09, p=0.045). The age and sex of patients were not predictors of change for HGS (p=0.903 and p=0.434, respectively). It is crucial to note the considerable degree of heterogeneity between these studies ( $I^2=89.69\%$ , p<0.0001).

## 3.3.2 | Knee Extensor Strength

Eight studies assessed KES (Table S4). Four of these identified a reduction in KES during hospitalisation lasting 8–14 days [69, 84, 85, 97]. In contrast, other studies observed no change [91] or increased [32, 67, 101] KES within 7–10 days.

## 3.4 | Muscle Mass

#### 3.4.1 | Whole-Body Muscle Mass

Eight studies presented findings for whole-body muscle mass, typically assessed by skeletal muscle mass (SMM) either as a percentage of body mass or via the skeletal muscle index (SMI) although, some studies expressed this as lean body mass index (LBMI) or fat-free mass (FFM) (Table S5). The majority of studies observed a decline in whole-body muscle mass [55, 56, 81, 101, 102] between 7 and 36 days across various exposures and illnesses in medical wards, ICU and a combination of both. Some studies observed no change [24, 84] and nonsignificant increases [81, 93] during 6–21 days of hospitalisation. Of

Author/ reference	Year of publication	Study design	Sample size	Nature of exposure	Length of hospital stay (days)	Acute sarcopenia assessed?	HGS assessed?	Knee extensor strength assessed?	Muscle mass assessed?	Muscle function assessed?	Muscle quality assessed?
Aarden et al. [24]	2021	Prospective, observational cohort study	N=343	Medical wards (CV, GI, pulmonary, infection, other)	5.7 (IQR: 3.9–8.7)	×	~	×	~	>	×
Ahmad et al. [25]	2024	Randomised controlled trial	N = 15	Surgical wards (heart valve surgery)	$10.64 \pm 3.79$	×	×	×	×	`	×
Annetta et al. [26]	2017	Prospective, observational cohort study	N = 20	ICU Wards (Trauma)	ICU=22 (IQR: 16-37)	×	×	×	>	×	×
Attaway et al. [ <b>27</b> ]	2022	Retrospective analysis of prospective cohort study	COVID-19 Cohort: $N = 95$ , Alive: $N = 79$ , Died: $N = 16$	ICU and medical wards (COVID-19)	Alive=13.0 (IQR, 6.0, 28.0). Died=21.0 (IQR, 13.8, 37.3)	×	×	×	>	×	×
Ballesteros- Pomar et al. [28]	2021	Prospective, observational cohort study	N = 200	Medical wards (cardiorespiratory, digestive, nephrological, oncological)	7 (IQR: 7)	`	>	`	>	`	×
Bao et al. [29]	2022	Randomised controlled trial	N=20	ICU Wards (pelvic fracture, thoracolumbar fracture, multiple rib fractures, haemorrhagic shock, lung infection, other)	12.2±4.18	×	×	×	>	×	×
Barbalho et al. [30]	2019	Within-patient randomised trial	N = 20	ICU wards	$11 \pm 2.2$	×	×	×	>	×	×
Beyer et al. [31]	2011	Randomised controlled trial	N = 14	Medical wards (acute infection)	24.5 (19–64)	×	>	×	>	×	×
Bodilsen et al. [32]	2013	Prospective, observational cohort study	N=33	Medical wards (CV, GI, pulmonary, infection, other)	7.5 (IQR: 4.25-11.00)	×	`	>	×	>	×
Bologna & Pone [33]	2022	Retrospective analysis of randomised and observational trial	N=40	ICU wards (COVID-19)	20.1	×	>	×	>	×	×
Borges et al. [34]	2016	Randomised controlled trial	N = 19	CABG surgery	8.3 ± 2.2	×	×	×	×	>	×
											(Continues)

**TABLE 1** | Included studies and their characteristics.

TABLE 1 | (Continued)

6 of 21

Author/ reference	Year of publication	Study design	Sample size	Nature of exposure	Length of hospital stay (days)	Acute sarcopenia assessed?	HGS assessed?	Knee extensor strength assessed?	Muscle mass assessed?	Muscle function assessed?	Muscle quality assessed?
Borges et al. [15]	2020	Prospective, observational cohort study	N=45	ICU wards (severe sepsis or septic shock)	20 (11.0–31.5 (25th–75th percentile))	×	>	×	>	×	×
Bradford et al. [35]	2023	Retrospective, observational cohort study	N = 81	ICU Wards (Trauma)	38±21	×	×	×	>	×	×
Butera et al. [36]	2023	Retrospective, observational cohort study	N=697	Medical and surgical wards (joint arthroplasty, pneumonia, heart failure, COPD, hip fracture)	18±12.1	×	×	×	×	`	×
Chapple et al. [37]	2022	Randomised controlled trial	N=42	ICU wards (CV, respiratory, GI, neurological, sepsis, trauma, other)	< 60 days	×	×	×	>	×	×
Chites et al. [38]	2021	Prospective, observational cohort study	N = 600	Medical, surgical and ICU wards	NR	×	>	×	×	×	×
da Silva et al. [39]	2022	Prospective, longitudinal cohort study	N = 41	ICU wards (burns)	24 (IQR: 16-40)	×	`	×	×	×	×
De Andrade- Junior et al. [40]	2021	Prospective, observational cohort study	N=32	ICU wards (COVID-19)	21 (15–42 (range))	×	>	×	>	×	>
de Buyser et al. [41]	2014	Prospective, observational cohort study	N=639	Medical wards (hypertension, ischaemic heart disease, heart failure, type II diabetes, osteoarthritis, COPD, renal failure)	9 (IQR: 6-14)	×	>	×	×	`	×
de Carvalho et al. [ <b>42</b> ]	2022	Prospective, observational cohort study	N = 1168	Medical and surgical wards	Men = 7.86 ± 10.28; Female = 7.33 ± 9.61	×	`	×	×	×	×
de Morton et al. [43]	2007	Randomised controlled trial	N=126	Medical wards (respiratory, circulatory, digestive, genitourinary, other)	6 (IQR: 3.25–9.75) days	×	×	×	×	`	×
de Moura et al. [44]	2023	Prospective, observational cohort study	N=30	ICU wards (COVID-19)	7	×	×	×	`	×	*
											(Continues)

TABLE 1 | (Continued)

Author/ reference	Year of publication	Study design	Sample size	Nature of exposure	Length of hospital stay (days)	Acute sarcopenia assessed?	HGS assessed?	Knee extensor strength assessed?	Muscle mass assessed?	Muscle function assessed?	Muscle quality assessed?
Dimopoulos et al. [3]	2020	Prospective, observational cohort study	N=165	ICU wards (Cardiac surgery)	w	×	×	×	~	×	×
Dirks et al. [45]	2015	Observational, clinical trial	N=9	ICU wards (comatose)	Not reported	×	×	×	`	×	×
Dusseaux et al. [46]	2019	Prospective, observational cohort study	N=25	ICU wards (Medical: septic shock, sepsis, acute severe pancreatitis, cardiac arrest, pneumonia, endocarditis)	10.9±4.7	×	×	×	>	×	>
Eibel et al. [47]	2022	Randomised controlled trial	N=6	Surgical wards (CABG)	7	×	×	×	×	>	×
Fränzel et al. [48]	2024	Randomised controlled trial	N = 29	Medical wards (various)	21	×	×	×	×	>	×
Gerovasili et al. <b>[49]</b>	2009	Prospective, observational controlled trial	N = 13	ICU wards (sepsis, trauma, neurologic, other)	Not reported	×	×	×	>	×	×
Giangregorio et al. [ <b>50</b> ]	2009	Randomised controlled trial	N=7	Surgical wards (hip fracture)	$26.1 \pm 17.6$	×	×	×	×	>	×
Gil et al. [51]	2022	Prospective, observational, cohort study	N = 80	Medical and ICU wards (COVID-19)	8 (IQR: 5-12)	×	`	×	>	×	×
Gualtieri et al. [52]	2020	Prospective, observational, cohort study	N=30	ICU wards (COVID-19)	Not reported	×	×	×	>	×	>
Hadda et al. [53]	2018	Prospective, observational, cohort study	N = 70	ICU wards (sepsis)	7	×	×	×	>	×	×
Haines et al. [54]	2019	Prospective, observational cohort study	N = 107	ICU wards (trauma)	39.00 [19.00, 65.50] (Median (IQR)); ICU =11.33 [5.54, 25.14] (Median (IQR))	`	×	×	>	×	×
Hasanloei et al. [ <mark>55</mark> ]	2021a	Randomised controlled trial	N = 50	ICU wards (CV, trauma, GI, respiratory, CNS)	44.28±9.31	×	×	×	>	×	×
Hasanloei et al. [ <b>56</b> ]	2021b	Randomised controlled trial	N = 20	ICU wards (trauma)	$19.15 \pm 8.46$ (ICU = 13.35 \pm 5.55)	×	×	×	`	×	×
											(Continues)

(Continued)
—
L
Ш
Г
<b>A</b>
E i

Author/ reference	Year of publication	Study design	Sample size	Nature of exposure	Length of hospital stay (days)	Acute sarcopenia assessed?	HGS assessed?	Knee extensor strength assessed?	Muscle mass assessed?	Muscle function assessed?	Muscle quality assessed?
Hayes et al. [57]	2018	Prospective, observational cohort study	N=25	ICU wards (medical & surgical: various)	20	×	×	×	~	×	>
Hickson et al. [58]	2004	Randomised controlled trial	N = 300	Medical wards (various)	23.0 (IQR: 14-39)	×	>	×	×	×	×
Hu et al. [59]	2020	Randomised controlled trial	N=50	Medical wards (infection, cardiac, respiratory, GI, neurological, endocrine, other)	<b>6.92</b> ±4.08	×	>	×	×	>	×
Jones et al. [60]	2006	Randomised controlled trial	N = 80	Medical wards (various)	11 (IQR: 6–21) days	×	×	×	×	>	×
Kangalgil et al. [61]	2022	Prospective, observational cohort study	N=35	ICU wards (surgical & trauma)	7	×	×	×	>	×	×
Kangalgil et al. [62]	2024	Prospective, observational cohort study	N=44	ICU wards (various	7	×	×	×	>	×	×
Karlsen et al. [63]	2017	Prospective, observational cohort study	N=151	Medical wards (respiratory, infection, MSK, genitourinary, digestive, endocrine, neurological, other)	3–13	×	`	×	×	`	×
Katari et al. [64]	2018	Prospective, observational, cohort study	N = 100	Surgical and medical ICU patients	NR	×	×	×	>	×	×
Kim et al. [65]	2023	Prospective, observational, cohort study	N = 58 (hip fracture); $N = 57$ (hip disease)	Surgical wards (hip fracture). Medical wards (hip disease)	Hip fracture = 10.2. Hip disease = 8.7	×	>	×	×	×	×
Kouw et al. [66]	2019	Prospective, observational cohort study	N = 26	Surgical wards (THA)	5.6±0.3	×	>	×	>	×	>
Kronborg et al. [67]	2017	Randomised, assessor- blinded effectiveness study	N=45	Surgical wards (hip fracture)	11.8±6.8	×	×	`	×	`	×
											(Continues)

TABLE 1 | (Continued)

						A 01140		Knee	Missio	Musulo	Musula
Author/ reference	Year of publication	Study design	Sample size	Nature of exposure	Length of hospital stay (days)	sarcopenia assessed?	HGS assessed?	strength assessed?	mass assessed?	function assessed?	quality assessed?
Lee et al. [4]	2021	Prospective, observational cohort study	N=86	Medical and surgical ICU wards (CV, respiratory, GI, neurological, sepsis, trauma, metabolic, renal, immunocompromised)	17.43 (IQR: 10.69–36.68)	×	×	×	>	×	~
López Jiménez et al. [68]	2024	Prospective, observational cohort study	N=98	Medical wards (heart failure, coronary artery disease, pulmonary infection, urinary infection)	7.6 ± 4.3	×	>	×	>	×	×
Martín- Salvador et al. [69]	2015	Prospective, observational cohort study	<pre>&gt; 75years old N=48; &lt; 75years old N=68</pre>	Medical wards (pneumonia)	> 75 years old 8.05 ± 3.1. < 75 years old 8.33 ± 3.9	×	`	>	×	`	×
Martínez- Velilla et al. [ <mark>70</mark> ]	2019	RCT	N=185	Medical wards (CV, infection, pulmonary, GI, neurological, other)	8 (IQR: 4)	×	>	×	×	>	×
Martone et al. [71]	2017	Observational cohort study	N = 394	Medical wards (heart disease, diabetes, stroke, other)	$10.2 \pm 8.1$	`	`	×	>	`	×
Mayer et al. [ <b>72</b> ]	2020	Prospective, observational, cohort study	N=41	ICU wards (medical or cardiothoracic)	11.2 (IQR: 8–19), ICU = 8 (4)	×	`	>	>	`	>
McNelly et al. [73]	2020	Multicentre, interventional, single-blind RCT	N = 121	ICU wards (multiorgan failure)	22.8 (IQR: 1.5–183)	×	×	×	>	×	×
Mets et al. [74]	2004	Single-blind, prospective, randomised controlled trial	N = 15	Medical wards (acute infection with high circulating inflammation)	Not reported	×	`	×	×	×	×
Mgbemena et al. [75]	2022	Prospective, observational cohort study	N = 101	Surgical wards (cardiac)	$11 \pm 5$	×	`	×	×	×	×
Nakanishi et al. [76]	2020	Multicentre, prospective, observational, cohort study	N = 64	Surgical and medical ICU wards (respiratory, sepsis, cardiac)	38 (IQR: 18–57)	×	×	×	>	×	×
Nery et al. [77]	2012	Controlled trial	N = 15	Surgical wards (lung resection)	Not reported	×	×	×	×	`	×
											(Continues)

(Continued)
LE 1
TAB]

Author/ reference	Year of publication	Study design	Sample size	Nature of exposure	Length of hospital stay (days)	Acute sarcopenia assessed?	HGS assessed?	Knee extensor strength assessed?	Muscle mass assessed?	Muscle function assessed?	Muscle quality assessed?
Neto et al. [78]	2024	Randomised controlled trial	N=30	ICU wards (COVID-19)	4.66±2.99	×	>	×	×	×	×
Nickels et al. [79]	2020	Single- blinded, RCT	<i>N</i> =36	ICU wards (sepsis, trauma, cardiac, G1, pneumonia, vascular, airway obstruction, overdose, other)	17.9 (IQR: 13.0, 29.4)	×	>	×	>	>	×
Norheim et al. [80]	2017	Prospective, observational, cohort study	Continuous inflammation: N=138. Became noninflammatory: N=76	Medical wards (acute illness with high circulating inflammation)	CI = 11.0 (IQR: 8–15). BNI = 8.0 (IQR: 6–11)	×	>	×	×	>	×
Ogasawara et al. [ <b>81</b> ]	2018	Randomised controlled trial	N = 21	Medical wards (COPD)	$12.1 \pm 3.9$	×	×	×	>	×	×
Ortiz-Alonso et al. [82]	2019	Randomised controlled trial	N=125	Medical wards (respiratory, circulatory, renal/neurologic, CNS, digestive)	7 (IQR: 5)	×	×	×	×	>	×
Parry et al. [83]	2015	Prospective, observational, cohort study	N = 22	ICU wards (medical and surgical)	22.0 (IQR: 12.8-43.5)	×	×	×	>	×	>
Pitta et al. [84]	2006	Prospective, observational, cohort study	N = 17	Medical wards (COPD)	∞	×	×	>	`	×	×
Pourhassan et al. [85]	2020	Prospective, longitudinal, observational, cohort study	N=41	Medical wards (falls and fractures, pneumonia, OA, stroke, UTI)	16 (14–18)	×	>	>	>	×	×
Puthucheary et al. [86]	2013	Prospective, observational, cohort study	N = 63	ICU wards (sepsis, trauma, acute liver failure, cardiogenic shock)	30 (11–334)	×	×	×	>	×	×
Ramsey et al. [87]	2022	Longitudinal, observational, cohort study	N=572	Medical wards (MSK, neurological, infection, CV, respiratory, other)	19.8 (IQR: 13.6–28.9)	×	`	×	×	>	×
Raymond et al. [88]	2017	Randomised controlled trial	N=232	Medical wards (fractures, falls, respiratory, renal, cardiac, neurological, dementia, MSK, other)	12.2 (95% CI: 11–13.5)	×	×	×	×	`	×
											(Continues)

(Continued)
1
TABLE

Muscle quality ssessed?	×	×	×	>	>	×	×	×	×	×	>	×
Muscle function assessed? a	×	×	×	×	×	×	>	×	`	×	×	*
Muscle mass assessed?	`	>	>	>	>	`	×	`	×	`	>	`
Knee extensor strength assessed?	×	×	>	×	×	×	×	×	>	×	×	×
HGS assessed?	×	>	×	×	>	×	×	×	×	×	×	×
Acute sarcopenia assessed?	×	×	×	×	×	×	×	×	×	×	×	×
Length of hospital stay (days)	34.5 (25%–75% quartile, 17–54)	Not reported	Not reported	42 (95% CI, 20–56)	2	ALL = 29 (19-45 (median IQR). Low APTMA = 19 (IQR: 15-29). Moderate APTMA = 29 (IQR: 20- 39). High APTMA = 48 (IQR: 31-61)	4	7	10.38±2.47	25 (IQR: 20-33)	10	14
Nature of exposure	ICU wards (respiratory, sepsis, cardiac, coma, other)	ICU wards (medical, surgical, trauma)	ICU wards (abdominal, cardiac, GI, respiratory, organ transplant, thoracic, other)	ICU wards (TBI)	Medical wards (arthrosis, MSK)	ICU wards (trauma)	Surgical wards (THA)	ICU wards (sepsis, stroke, lung transplant, cardiac insufficiency)	Medical wards (COPD)	ICU wards (tetanus infection)	ICU wards (various)	ICU wards (respiratory, cardiac, neurological, other)
Sample size	N = 60	N = 44	N=47	N = 30	N = 10	N=114	N = 40	N=74	N = 29	N = 80	N = 22	N=23
Study design	Prospective, observational, cohort study	Prospective, observational, pilot study	Randomised controlled trial	Randomised controlled trial	Randomised controlled trial	Retrospective cohort study	Randomised controlled trial	Prospective, observational cohort study	Randomised controlled trial	Prospective, observational, cohort study	Prospective, observational, cohort study	Randomised controlled trial
Year of publication	2021	2017	2021	2019	2023	2022	2022	2021	2017	2019	2016	2023
Author/ reference	Rodrigues et al. [89]	Segaran et al. [90]	Segers et al. [91]	Silva et al. [92]	Strasser et al. [93]	Tazerout et al. [94]	Temporiti et al. [ <mark>95</mark> ]	Toledo et al. [96]	Torres- Sanchez et al. [97]	Trung et al. [98]	Turton et al. [99]	Verceles et al. [100]

(Continued)
[ABLE 1

Author/ reference	Year of publication	Study design	Sample size	Nature of exposure	Length of hospital stay (days)	Acute sarcopenia assessed?	HGS assessed?	Knee extensor strength assessed?	Muscle mass assessed?	Muscle function assessed?	Muscle quality assessed?
Vermeeren et al. [101]	2004	Randomised controlled trial	N = 24	Medical wards (COPD)	×	×	>	>	>	×	×
Welch et al. [102]	2022a	Prospective, observational cohort study	N = 79	Surgical and medical wards (emergency surgery, colorectal surgery, infection)	Not reported	`	>	×	>	>	>
Welch et al. [103]	2022b	Prospective, observational cohort study	N=79	Surgical and medical wards (emergency surgery, colorectal surgery, infection)	Not reported	>	>	×	>	>	>
Werner et al. [104]	2024	Prospective, observational cohort study	N = 107	Medical wards (MSK, neurological, infection, CV, GI, other)	20.2±5.8	×	>	×	×	>	×
Wnuk et al. [105]	2016	Single-blind RCT	N = 16	Surgical wards (abdominal aortic aneurysm)	$6.56 \pm 0.73$	×	×	×	×	>	×
Wu et al. [106]	2023	Multicentre RCT	N = 28	ICU wards (lung disease, sepsis, CKD, acute pancreatitis, other)	13.05 (IQR: 7.25–28.25)	×	>	×	×	>	×
Xie et al. [107]	2019	Prospective, observational, cohort study	<i>N</i> = 95, ICU-AW Group: <i>N</i> = 50. Non-ICU-AW Group: <i>N</i> = 45	ICU wards (pneumonia, COPD, pulmonary, ARDS)	ICU-AW = 20.54±6.37; NON- ICU-AW = 17.76±4.93	×	×	×	>	×	×
Xue et al. [95, 108]	2022	Randomised controlled trial	N = 43	Surgical wards (cardiac surgery)	$8.16 \pm 1.13$	×	×	×	×	>	×
Abbreviations: AP kidney disease; CN ICU-AW = intensiv RCT = randomised	TMA = acute pos VS = central nervo e care unit-acqui controlled trial;	t-trauma muscle atroj ous system; COPD = cl ired weakness; IQR = TBI = traumatic brain	phy: ARDS=acute res hronic obstructive pul interquartile range; k iniurv: TBI=trauma	piratory distress syndrome; BNI monary disease; CV=cardiovase (ES=knee extensor strength; Los tic brain iniury: THA = total hip.	=became noninflammatory cular; FL =fascicle length; G S = length of hospital stay; M arthronlasty: UTT = urinary; M	CABG = corona [ = gastrointestin SK = musculoske ract infection: V	ry artery bypa. al; HGS= hanc eletal; NR = not I = vastus inter	ss graft; CI = co dgrip strength; I t reported; OA = rmedius; VL = v	ntinuous infla (CU = intensive : osteoarthritis; astus lateralis.	mmation; CKD : care unit; : PA = pennatio	= chronic 1 angle;

First author (year)	Sex	Duration (day)				Weight	SMD	[95%	CI]
Mbgemena et al. (2022)	M/F	11	<b>⊢</b> ∎–1			0.92%	-0.78 [	-1.00, -	0.56]
Neto et al. (2024)	M/F	5	<b>⊢</b>	-i		0.81%	-0.39 [	-0.76, -	0.01]
Welch et al. (2022)	F	7	<b>⊢</b>	<u> </u>		2.89%	-0.19	[-0.55,	0.16]
Welch et al. (2022)	Μ	7	н	i i		3.10%	-0.11	[-0.40,	0.17]
Bodilsen et al. (2013)	M	8		•		1.06%	-0.09	[-0.66,	0.48]
Bodilsen et al. (2013)	F	8	H	•		1.02%	-0.08	[-0.67,	0.52]
Karlsen et al. (2017)	M/F	13	⊢	÷		0.92%	-0.04	[-0.26,	0.18]
Pourhassan et al. (2020) (non-mal.)	M	14	H	÷		0.99%	-0.02	[-0.72,	0.67]
Pourhassan et al. (2020) (mal.)	M	12	H	+		0.42%	6 0.00	[-1.13,	1.13]
Pourhassan et al. (2020) (non-mal.)	F	14	-	÷ 1		1.74%	6 0.00	[-0.38,	0.38]
Aarden et al. (2021)	M	6		- <b>i</b> -i		12.95%	6 0.01	[-0.14,	0.16]
Aarden et al. (2021)	F	6		- <b>i</b>		12.94%	6 0.02	[-0.13,	0.17]
Chites et al. (2021)	Μ	14	F			5.18%	6 0.04	[-0.20,	0.28]
Chites et al. (2021)	F	14	٠	- <b></b>		5.20%	6 0.06	[-0.18,	0.29]
Kim et al. (2023) (medical)	M/F	9	۰			4.40%	6 0.08	[-0.18,	0.34]
Ramsey et al. (2022)	M	20		н <b>а</b> н		17.07%	6 0.10	[-0.04,	0.24]
Strasser et al. (2023)	M/F	7		֥		0.60%	6 0.14	[-0.48,	0.76]
Hu et al. (2020)	M	7	H	÷•••		2.04%	6 0.19	[-0.21,	0.58]
Hu et al. (2020)	F	7	F	֥		2.04%	6 0.20	[-0.19,	0.60]
Ramsey et al. (2022)	F	20		H		17.22	% 0.21	[ 0.09,	0.33]
Wu et al. (2023)	M/F	14		÷•••		0.80%	6 0.24	[-0.14,	0.61]
Kim et al. (2023) (surgery)	M/F	10		) <b>——</b> —		4.39	% 0.30	[0.04,	0.56]
Pourhassan et al. (2020) (mal.)	F	13		÷ •		0.51%	6 0.40	[-0.62,	1.42]
Borges et al. (2020)	M/F	20			<b></b>	0.80	% 1.20	[ 0.82,	1.58]
Hetereogeneity: I^2 = 89.7%, p=0.67			-	•		100%	6 0.05	[-0.18,	0.28]
		Γ	1	1		7			
		-2	-1	0	1	2			
	Standardised mean difference (SMD)								

**FIGURE 2** | Meta-analysis illustrating changes in HGS during hospitalisation (F=Female; M=Male; mal.=malnourished; non-mal.=non-malnourished).

these studies, one identified a nonsignificant increase in muscle mass when reported as LBMI, but when measured by SMI, this showed a nonsignificant decrease [81]. The methods of measurement across studies assessing whole-body muscle mass were BIA and isotopic potassium. showed hospital length of stay or duration between scans in that exposure did statistically influence the changes in RFCSA ( $\theta = -0.04$ , 95% CI = -0.077:-0.011, p = 0.012), whereas age did not (p = 0.129). It is imperative to note the substantial heterogeneity within these studies ( $I^2 = 74.94\%$ , p < 0.001).

## 3.4.2 | Muscle Mass of Specific Muscles

Table S6 details findings from 12 studies that investigated muscle mass changes in the erector spinae, pectoralis, L3 and L4 psoas, abdominal muscles, biceps brachii, adductor pollicis, forearm and thigh muscles. All studies demonstrated declines in muscle mass in medical, surgical and ICU patients [27, 35, 37, 44, 46, 52–54, 76, 89, 90, 94]. Within one of these studies, the highest incidence of sarcopenia development was observed at 59% in ICU trauma patients over 44 days [54]. Two subgroups within this same study were the only exceptions where no change was observed in abdominal muscle mass in line with the L3 psoas region although there were significant reductions in the L4 psoas muscle [38]. These two subgroups had either died or were in ICU on day 10 after hospital admission or had been discharged from ICU and were alive on day 10 [38].

#### 3.4.3 | Rectus Femoris Cross-Sectional Area (RFCSA)

A meta-analysis was conducted on studies that offered sufficient data regarding changes in RFCSA during hospitalisation (n=9). Analysis revealed significant reductions in RFCSA with a moderate effect size (SMD=-0.67, 95% CI=-0.92:-0.43, p < 0.001; Figure 3). This equates to a 16.5% reduction in RFCSA between 3 and 21 days. Ultrasound and CT scans were the tools utilised for this assessment. Furthermore, a meta-regression

#### 3.4.4 | Muscle Mass of Lower Limbs

Thirty-five studies assessed changes in lower limb muscle mass (Table S7). Assessment measures included thickness, volume and CSA of specific muscle groups such as the quadriceps, mid-thigh region, vastus lateralis, vastus intermedius, tibialis anterior and RF. Techniques employed were ultrasound, CT and MRI scans, with some studies using muscle biopsies to measure muscle fibre CSA.

All studies reported some degree of reduction in muscle mass of the lower limbs [3, 4, 15, 26, 29, 30, 33, 37, 40, 44, 45, 49, 51, 53, 57, 61, 62, 64, 66, 68, 72, 73, 76, 79, 83, 85, 86, 89, 91, 92, 96, 98–100, 107] over periods ranging from 6 to 60 days across diverse hospital exposures and illnesses. Kouw et al. [66] observed a decrease in muscle mass assessed by CT scans, but muscle biopsy data highlighted an increase in Type I and II muscle fibre CSA over 5.6 days.

# 3.5 | Muscle Function

Muscle function changes during hospitalisation were assessed in 26 studies (Table S8). Various tools measured muscle function, including the SPPB, TUG, 6MWT, chair stand test (CST) and gait speed. Meta-analyses were able to be conducted for the SPPB, TUG, 6MWT and gait speed during hospitalisation.

First author (year)	Sex	Duration (day)					Weight	SMD	[95% CI]
Hayes et al. (2018)	M/F	20	<u> </u>				4.64%	-1.33 [-1	.95, -0.72]
Kouw et al. (2019)	M/F	6	⊢				4.96%	-1.13 [-1	.62, -0.64]
Borges et al. (2020)	M/F	20	1				6.01%	-1.02 [-1	.38, -0.66]
Kangalgil et al. (2022)	M/F	7	,				5.66%	-0.98 [-1	.39, -0.58]
Lee et al. (2021)	M/F	13	F				6.55%	-0.95 [-1	.43, -0.47]
Lee et al. (2021)	M/F	21	F				4.15%	-0.84 [-1	.57, -0.12]
Hayes et al. (2018)	M/F	10		·	4		5.85%	-0.82 [-1	.29, -0.34]
Xie et al. (2019)	M/F	7		⊢∎⊣			8.51%	-0.78 [-1	.10, -0.47]
Mayer et al. (2020)	M/F	7		<b>—</b>	4		6.17%	-0.70 [-1	.04, -0.36]
Xie et al. (2019)	M/F	7		н	∎		8.69%	-0.34 [-0	0.64, -0.04]
Lee et al. (2021)	M/F	6		н	<b>-</b>		9.09%	-0.31 [-0	).58, -0.03]
de Moura et al. (2023) (left leg)	M/F	3					5.06%	-0.25 [-	0.81, 0.30]
Lopez Jimenez et al. (2024) (right leg)	M/F	8		F	<b>.</b>		10.07%	-0.22 [-	0.45, 0.01]
Lopez Jimenez et al. (2024) (left leg)	M/F	8		F	-		10.07%	-0.22 [-	0.45, 0.01]
de Moura et al. (2023) (right leg)	M/F	3					4.52%	-0.17 [-	0.80, 0.45]
Hetereogeneity: I^2 = 74.9%, p<0.0001				•			100%	-0.67 [-0	).92, -0.43]
							_		
			-2	-1	0	1	2		
		Standardised mean difference (SMD)							

FIGURE 3 | Meta-analysis illustrating changes in RFCSA during hospitalisation.

Muscle function declined in seven studies across the 6MWT, TUG and gait speed, predominantly related to a surgical context [25, 34, 47, 69, 77, 95, 105].

In studies not related to surgical procedures, muscle function remained stable or improved [24, 32, 59, 63, 70, 72, 80] over 3–13 days.

Meta-analyses were conducted where data were sufficient for SPPB (n=4), 6MWT (n=5), TUG (n=6) and gait speed (n=3). Analyses revealed significant improvements in the SPPB (SMD = 0.86, 95% CI = 0.03:1.69, p=0.046) with neither length of stay nor age being significant predictors (p=0.51 and p=0.36, respectively). There were no significant changes to 6MWT, TUG or gait speed during hospitalisation (p=0.22, p=0.46 and p=0.98, respectively). However, meta-regressions revealed age as a significant predictor for TUG ( $\theta=-0.11$ , 95% CI=-0.018:-0.005, p=0.009). It is important to note the substantial heterogeneity between the studies for the SPPB ( $I^2=95.51\%$ , p<0.001), 6MWT ( $I^2=94.3\%$ , p<0.001), TUG ( $I^2=96.23\%$ , p<0.001) and gait speed ( $I^2=98.8\%$ , p<0.001).

Sensitivity analyses were performed for the gait speed meta-analysis. Analyses showed that removing Butera et al. [36] (SMD=-0.62, 95% CI=-16.733:15.501, p=0.712,  $I^2$ =98.27%, p<0.001), Fränzel et al. [48] (SMD=-0.37, 95% CI=-19.521:18.778, p=0.846,  $I^2$ =99.19%, p<0.001) and Temporiti et al. [95] (SMD=0.93, 95% CI=-2.065:3.916, p=0.159,  $I^2$ =80.02%, p=0.025) individually did not significantly influence overall changes in gait speed (Figure 4).

# 3.6 | Muscle Quality Indices

Twelve studies provided data for various muscle quality indices, utilising methods such as ultrasound, CT scans and BIA (Table S9). The indices measured included echogenicity, pennation angle, fascicle length, muscle attenuation and phase angle. Echogenicity showed an increase—indicating a reduction in muscle quality—in nearly all patient groups [40, 57, 72, 83, 92]. A decline in muscle attenuation was also observed in specific patient groups via CT scan [46, 52, 66]. Reductions were also observed in phase angle [93, 102, 103]. No changes were observed in muscle attenuation in obese patients [52] or in echogenicity in only one study [4]. Lee et al. [4] also identified an improvement in fascicle length; however, this coincided with a reduction in pennation angle. Another study identified reductions in pennation angle and fascicle length [99]. These alterations were observed over periods spanning 6–22 days.

# 4 | Discussion

This systematic review and meta-analysis aimed to determine the incidence of acute sarcopenia development and identify the changes that occur to muscle strength, mass, quality and function within hospitalised patients. The key findings of this review are (1) specific assessment of acute sarcopenia is very rarely conducted; (2) when assessed, its overall incidence is 18% but it varies considerably between groups of patients and possibly due to differences in methods of assessment; (3) it can develop rapidly, in as quickly as 4 days; and (4) muscle mass and quality indices, especially in the lower limbs, are more affected than upper limb strength or overall muscle function during hospitalisation. Our findings suggest that HGS and muscle function assessments may not be suitable for evaluating acute changes in muscle health in hospital settings. Relying on these tests may lead to underdiagnosis of acute muscle health deterioration and impact patient well-being during and after hospitalisation.

First author (year)	Sex	Duration (day)	SMD (95% CI)	Weight SMD [95% Cl]
SPPB			:	
Xue et al. (2022)	M/F	8	<b>⊢</b> ∎→1	5.79% 1.17 [0.78, 1.56]
Ortiz-Alonso et al. (2019)	M/F	7	i=-	5.93% 0.17 [-0.01, 0.35]
Franzel et al. (2024)	M/F	21	<b>⊢</b> ∎1	5.76% 0.85 [ 0.42, 1.27]
Butera et al. (2024)	M/F	19		5.95% 1.27 [1.17, 1.37]
Pooled (I^2 = 95.5%, p = 0.045)				0.86 [ 0.03, 1.69]
6MWT				
Xue et al. (2022)	M/F	8	÷ +=-1	5.81% 1.07 [0.69, 1.44]
Nery et al. (2012)	M/F	7	<b>⊢_</b> ∎4 ≟	5.35% -1.64 [-2.42, -0.87]
Eibel et al. (2022)	M	7		4.29% -2.09 [-3.52, -0.66]
Borges et al. (2020)	M/F	8	<b>⊢</b> ∎÷i	5.73% -0.31 [-0.77, 0.15]
Ahmad et al. (2024)	M/F	11		5.28% -1.80 [-2.62, -0.98]
Pooled (I^2 = 94.3%, p = 0.2)				-0.88 [-2.56, 0.80]
TUG				
Temporiti et al. (2022)	M/F	4	<b>⊢</b> ∎1	5.77% 1.29 [ 0.87, 1.71]
Hu et al. (2020)	M/F	7	F==-1	5.87% -0.39 [-0.68, -0.10]
Giangregorio et al. (2009)	M/F	26	→	3.59% -2.65 [-4.51, -0.79]
Franzel et al. (2024)	M/F	21	<b>⊢∎</b> →1 ⋮	5.77% -0.71 [-1.12, -0.29]
de Morton et al. (2007)	M/F	6	H <b>B</b> -)	5.90% -0.20 [-0.43, 0.03]
Bodilsen et al. (2013)	M/F	8	<b>⊢</b> ∎i	5.82% -0.43 [-0.78, -0.07]
Pooled (I^2 = 96.2%, p = 0.45)				-0.33 [-1.36, 0.71]
Gait Speed				
Butera et al. (2023)	M/F	19	HEN	5.94% 1.12 [ 1.00, 1.25]
Temporiti et al. (2022)	M/F	4	▶	5.67% -1.89 [-2.41, -1.37]
Franzel et al. (2024)	M/F	21	· · · · ·	5.78% 0.65 [ 0.25, 1.05]
Pooled (I^2 = 98.8%, p = 0.97)		-		-0.03 [-4.03, 3.98]

FIGURE 4 | Meta-analysis illustrating changes in muscle function during hospitalisation.

Assessment of sarcopenia, according to EWGSOP2 criteria [1], entails tests for several muscle parameters including strength, mass, quality and function. Commonly, HGS or CST are used to identify probable sarcopenia, which is confirmed by assessments of muscle mass or quality. Finally, severity is determined by muscle function tests. This process is rarely followed in clinical settings, and in most cases, assessment of muscle health is done by evaluating only one of the above-named parameters. Indeed, only four [28, 54, 71, 102] of the included studies assessed sarcopenia specifically. It is not clear why this is, but the complexity and time demands of conducting all tests coupled with the clinical condition of the patients may be relevant. Furthermore, the novelty of acute sarcopenia and the recent pandemic halting many research practices, such as gaining ethical approval and research grants [110], may mean that there have been delays in performing relevant studies.

The incidence of sarcopenia differed between studies. This is likely due to the presenting illness at hospital admissiontrauma patients in ICU had a higher incidence than medical or surgical patients. Different methodological approaches may have also contributed. For example, the highest incidence was reported by Haines et al. [54], who used abdomen muscle CSA to determine sarcopenia [111]. HGS is used as the primary determinant of sarcopenia in the most recent EWGSOP [1] criteria. Interestingly, this is one of the main changes compared with the former version where the primary determinant was muscle mass [109]. Studies comparing the two EWGSOP criteria for identifying sarcopenia in the same population consistently conclude that the EWGSOP1 [109] criteria return a higher sarcopenia prevalence than the EWGSOP2 [1] criteria [112, 113]. It therefore seems that muscle mass is more sensitive than muscle strength, and although this may result in several false positive cases for chronic sarcopenia, it may enhance the identification of people suffering from acute changes in muscle health and requiring suitable management strategies to attenuate this.

Our meta-analysis further supports that, as we showed that HGS was not affected by length of hospitalisation. This is surprising especially when coupled with significant reductions in muscle mass. However, given the various presenting conditions and physical capacity of patients upon hospital admission, initial HGS assessments are unlikely to represent maximal effort. Previous studies highlighted differences in submaximal and maximal HGS scores in community-dwelling and hospitalised patients and sarcopenia prevalence [114, 115]. One study indicated a near halving of sarcopenia prevalence based on submaximal HGS scores [114], potentially due to weakness on arrival and improved strength following treatment in hospital. Our findings support these studies [114, 115] and challenge the use of HGS as a standalone diagnostic criterion for sarcopenia in hospitalised settings.

Like HGS, muscle function assessments may not be suitable to diagnose acute sarcopenia in nonsurgical populations, as it requires effort from the patient. Patient mobility and functional capacity are likely to be limited upon hospital admission for reasons related to their condition rather than muscle health. Successful hospital treatment is likely to improve function to a greater extent than any detriment because of potential muscle losses. Specific muscle function tests have been used at hospital discharge, and lower functionality is associated with worse outcomes postdischarge [116]. Given the mental and physical fatigue and reduced motivation a patient may experience while recovering from illness in hospital, muscle assessments that require a level of effort to produce their 'best' performance may be influenced by these feelings. Therefore, it remains unclear whether such tests can truly reflect muscle health and function in hospitalised patients.

Conversely, our findings suggest that muscle mass and indices of muscle quality are reduced during hospitalisation, particularly in the lower limbs. Muscle mass and quality assessments differ to HGS and muscle function as they are objective and cannot be influenced by patient effort. Similarly to muscle mass, muscle quality indices were negatively affected, evidenced by unfavourable changes in muscle echogenicity and pennation angle in the quadriceps, muscle attenuation in the abdomen and erector spinae, and phase angle at a whole-body level. Although it is important to consider the variability in the measurement tools and the findings, this does provide some support for previous research that has promoted the prognostic importance of muscle quality indices in hospitalised patients, identifying that critical illness and surgical exposures are significantly associated with lower muscle quality [117, 118]. Muscle quality indices are becoming increasingly reported during hospitalisation as the assessment methods become more readily available, for example, using ultrasound. However, there is no criterion for any muscle quality indices in the EWGSOP2 definition for sarcopenia unlike other muscle parameters.

Changes in muscle parameters occur rapidly, regardless of age, and timely identification of muscle health deterioration is important. However, this is not the case in all hospitalised populations, and underlying health conditions would undoubtedly have an impact on the rate of change to muscle parameters. For example, populations in ICUs may experience higher inflammatory profiles promoting a more catabolic state. Fazzini et al. [12] identified rapid reductions in quadriceps muscle mass of approximately 2% per day in ICU. Hardy et al. [13] identified rapid muscle atrophy during the early stages of immobilisation with variable rates of atrophy in different muscles. Quadriceps and triceps surae showed the greatest rates of atrophy, particularly in critically ill patients versus healthy volunteers subjected to bed rest [13]. Such changes in muscle health have been reported to affect hospital length of stay, risk of complications and inhospital mortality [2-4, 76]; however, the long-term effects relating to the clinical significance, reversibility and changes within specific morbidities remain unknown with further research required.

Interestingly, our meta-regression results for HGS, RFCSA and all muscle function tests except TUG showed that age was not a predictor of change in these muscle parameters. This is surprising given that older populations are generally considered more vulnerable to the impact of acute illness on muscle health than younger adults. Our review included adults younger than 30 years old, demonstrating that individuals across all age groups are susceptible to reductions in muscle health during hospitalisation. Therefore, the incidence of acute sarcopenia and the observed reductions in muscle mass and quality may accelerate ageing across the entire adult population, potentially inducing conditions such as frailty, which has previously been identified in older adults [103].

Despite the above evidence, a timeline for the development of acute sarcopenia or for its optimal monitoring has not been established. Welch et al. [11] defined acute sarcopenia as changes in muscle mass and function developing within 28 days from a medical event. This timeline seems appropriate based on our findings and those mentioned previously [12, 13]. However, EWGSOP2 [1] suggests that acute sarcopenia is resolved within 6 months. The rationale for this is unclear as the impact of such rapid deteriorations of muscle health is unknown and may have dire consequences on patient wellbeing. Furthermore, there are no specific directions on when the baseline is to be established or when follow-up assessments should be conducted.

Finally, all definitions of sarcopenia base its diagnosis on muscle parameters reaching a specific threshold. Welch et al. [102] identified that, in addition to the number of participants developing acute sarcopenia, an extra 23% of participants lost over 10% of at least one other muscle parameter. Such reductions, even though not sufficient to classify sarcopenia, are likely to predispose them to significant health risks and further muscle health concerns in the long term [119]. This poses a question around the use of specific thresholds for identifying acute sarcopenia and whether the rate or magnitude of change should be considered.

## 4.1 | Limitations

Our study is limited by methodological variability in the included studies, evidenced by high heterogeneity in the meta-analyses. The heterogeneity was influenced by different measurement tools, variations in age, underlying health conditions and other demographic factors. These variables may influence our findings and could explain the inconsistencies we identified, thus questioning the comparability of our results. Furthermore, very few studies specifically assessed sarcopenia, even though all assessed at least one of the relevant muscle parameters. Often, the assessment of these parameters was a secondary outcome measure, and there was frequent underreporting of predata and postdata, as well as the omission of specific numbers of the cohort who experienced a decrease or increase in the muscle parameter in question. This limited our ability to perform additional meta-analyses and to attain a more thorough understanding of changes to muscle parameters during hospitalisation. Moreover, there is no set time for optimal muscle assessments during hospitalisation, so the time between assessments was variable, limiting our ability to establish a clear timeline for changes in muscle parameters.

The included studies also contained patients experiencing different hospital exposures. For example, patients were admitted to multiple exposures during one stay where measures of muscle health were obtained, such as ICU and medical wards. This diversity in patients made grouping these patients challenging and was not feasible in our analyses, meaning our results are difficult to extrapolate.

Additionally, although the search strategy devised was extensive and identified key papers in the area, a limitation of our study is the lack of further search terms, which may have resulted in missed related keywords (e.g., 'hospitalis\*' may be more appropriate than using 'hospitalization'). This could potentially affect the comprehensiveness of the search strategy.

# 5 | Conclusions and Future Directions

Sarcopenia can develop rapidly during the early stages of hospitalisation. Of the key parameters of muscle health involved in determining sarcopenia, we identified that muscle mass and quality are reduced during hospitalisation and muscle strength and function are not. This finding suggests that there may be widespread underdiagnosis of sarcopenia during hospitalisation and many patients may be discharged with compromised muscle health and greater risk of developing chronic sarcopenia. Therefore, sarcopenia assessments in clinical settings could be more reliable if objective assessments are prioritised early in hospitalisation, that is, muscle mass and muscle quality indices. Also, consideration needs to be given to the magnitude of reductions.

Our findings serve as a steppingstone towards fostering better collaboration and translational research for enhanced clinical practice in diagnosing and treating acute sarcopenia. However, methodological inconsistencies and the paucity of data suitable for meta-analyses limit our study. These limitations highlight current challenges while simultaneously laying the groundwork for future investigations. Future research should consider the limitations we have highlighted and focus on understanding the long-term effects of rapid muscle health deterioration on quality of life and postdischarge functional independence. Muscle quality indices should be considered seriously for incorporation into diagnostic criteria. Addressing these areas will deepen understanding of acute sarcopenia and guide more effective, individualised management strategies to attenuate reduced muscle health following hospitalisation.

#### Acknowledgements

This research was funded by Leeds Beckett University.

#### **Conflicts of Interest**

The authors declare no conflicts of interest.

#### References

1. A. J. Cruz-Jentoft, G. Bahat, J. Bauer, et al., "Sarcopenia: Revised European Consensus on Definition and Diagnosis," *Age and Ageing* 48 (2019): 16–31.

2. P. R. Kemp, R. Paul, A. C. Hinken, D. Neil, A. Russell, and M. J. Griffiths, "Metabolic Profiling Shows Pre-Existing Mitochondrial Dysfunction Contributes to Muscle Loss in a Model of ICU-Acquired Weakness," *Journal of Cachexia, Sarcopenia and Muscle* 11 (2020): 1321–1335.

3. S. Dimopoulos, V. Raidou, D. Elaiopoulos, et al., "Sonographic Muscle Mass Assessment in Patients After Cardiac Surgery," *World Journal of Cardiology*. 12 (2020): 351–361.

4. Z. Y. Lee, S. P. Ong, C. C. Ng, et al., "Association Between Ultrasound Quadriceps Muscle Status With Premorbid Functional Status and 60-Day Mortality in Mechanically Ventilated Critically Ill Patient: A Single-Center Prospective Observational Study," *Clinical Nutrition* 40 (2021): 1338–1347.

5. P. Srikanthan, T. B. Horwich, and C. H. Tseng, "Relation of Muscle Mass and Fat Mass to Cardiovascular Disease Mortality," *American Journal of Cardiology* 117 (2016): 1355–1360.

6. L. Dos Santos, E. S. Cyrino, M. Antunes, D. A. Santos, and L. B. Sardinha, "Sarcopenia and Physical Independence in Older Adults: The Independent and Synergic Role of Muscle Mass and Muscle Function," *Journal of Cachexia, Sarcopenia and Muscle* 8 (2017): 245–250.

7. C. M. Prado, S. A. Purcell, C. Alish, et al., "Implications of Low Muscle Mass Across the Continuum of Care: A Narrative Review," *Annals of Medicine* 50 (2018): 675–693.

8. A. M. Ryan, C. M. Prado, E. S. Sullivan, D. G. Power, and L. E. Daly, "Effects of Weight Loss and Sarcopenia on Response to Chemotherapy, Quality of Life, and Survival," *Nutrition* 67-68 (2019): 110539.

9. R. M. Dodds, H. E. Syddall, R. Cooper, et al., "Grip Strength Across the Life Course: Normative Data From Twelve British Studies," *PLoS ONE* 9 (2014): e113637.

10. W. J. Evans, J. Guralnik, P. Cawthon, et al., "Sarcopenia: No Consensus, No Diagnostic Criteria, and No Approved Indication—How Did We Get Here?," *Geroscience* 46 (2023): 183–190.

11. C. Welch, Z. K. Hassan-Smith, C. A. Greig, J. M. Lord, and T. A. Jackson, "Acute Sarcopenia Secondary to Hospitalisation—An Emerging Condition Affecting Older Adults," *Aging and Disease* 9 (2018): 151–164.

12. B. Fazzini, T. Markl, C. Costas, et al., "The Rate and Assessment of Muscle Wasting During Critical Illness: A Systematic Review and Meta-Analysis," *Critical Care* 27 (2023): 2.

13. E. J. O. Hardy, T. B. Inns, J. Hatt, et al., "The Time Course of Disuse Muscle Atrophy of the Lower Limb in Health and Disease," *Journal of Cachexia, Sarcopenia and Muscle* 13 (2022): 2616–2629.

14. J. G. Jespersen, U. R. Mikkelsen, A. Nedergaard, et al., "Alterations in Molecular Muscle Mass Regulators After 8 Days Immobilizing Special Forces Mission," *Scandinavian Journal of Medicine & Science in Sports* 25 (2015): 175–183.

15. R. C. Borges, H. V. Barbeiro, D. F. Barbeiro, and F. G. Soriano, "Muscle Degradation, Vitamin D and Systemic Inflammation in Hospitalized Septic Patients," *Journal of Critical Care* 56 (2020): 125–131.

16. S. E. Alway, J. S. Mohamed, and M. J. Myers, "Mitochondria Initiate and Regulate Sarcopenia," *Exercise and Sport Sciences Reviews* 45 (2017): 58–69.

17. Z. J. Liu and C. F. Zhu, "Causal Relationship Between Insulin Resistance and Sarcopenia," *Diabetology and Metabolic Syndrome* 15 (2023): 46.

18. M. J. Page, J. E. McKenzie, P. M. Bossuyt, et al., "The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews," *International Journal of Surgery* 88 (2021): 105906.

19. J. P. T. Higgins, J. Thomas, J. Chandler, et al., *Cochrane Handbook for Systematic Reviews of Interventions*, Second ed. (Hoboken, NJ: Wiley, 2020).

20. J. IntHout, J. P. Ioannidis, and G. F. Borm, "The Hartung-Knapp-Sidik-Jonkman Method for Random Effects Meta-Analysis Is Straightforward and Considerably Outperforms the Standard DerSimonian-Laird Method," *BMC Medical Research Methodology* 14 (2014): 25.

21. J. Cohen, *Statistical Power Analysis for the Behavioral Sciences*, Second ed. (Mahwah, NJ: Lawrence Erlbaum Associates, 1988).

22. J. J. Deeks, J. P. T. Higgins, J. Thomas, et al., *Chapter 10: Analysing Data and Undertaking Meta-Analyses* (Hoboken, NJ: Wiley, 2022).

23. W. Van den Noortgate, J. A. Lopez-Lopez, F. Marin-Martinez, and J. Sanchez-Meca, "Three-Level Meta-Analysis of Dependent Effect Sizes," *Behavior Research Methods* 45 (2013): 576–594.

24. J. J. Aarden, E. M. Reijnierse, M. van der Schaaf, et al., "Longitudinal Changes in Muscle Mass, Muscle Strength, and Physical Performance in Acutely Hospitalized Older Adults," *Journal of the American Medical Directors Association* 22, no. 839–45 (2021): e1.

25. A. M. Ahmad, S. A. Abusarea, B. Z. Fouad, S. A. Guirguis, and W. A. Shafie, "Effect of Adding Early Bedside Cycling to Inpatient Cardiac Rehabilitation on Physical Function and Length of Stay After Heart Valve Surgery: A Randomized Controlled Trial," *Archives of Physical Medicine and Rehabilitation* 105 (2024): 1050–1057.

26. M. G. Annetta, M. Pittiruti, D. Silvestri, et al., "Ultrasound Assessment of Rectus Femoris and Anterior Tibialis Muscles in Young Trauma Patients," *Annals of Intensive Care* 7 (2017): 104.

27. A. Attaway, N. Welch, D. Dasarathy, et al., "Acute Skeletal Muscle Loss in SARS-CoV-2 Infection Contributes to Poor Clinical Outcomes in COVID-19 Patients," *Journal of Cachexia, Sarcopenia and Muscle* 13 (2022): 2436–2446.

28. M. D. Ballesteros-Pomar, L. M. Gajete-Martin, B. Pintor-de-la-Maza, et al., "Disease-Related Malnutrition and Sarcopenia Predict Worse Outcome in Medical Inpatients: A Cohort Study," *Nutrients* 13, no. 9 (2021): 2937.

29. W. Bao, J. Yang, M. Li, et al., "Prevention of Muscle Atrophy in ICU Patients Without Nerve Injury by Neuromuscular Electrical Stimulation: A Randomized Controlled Study," *BMC Musculoskeletal Disorders*. 23 (2022): 780.

30. M. Barbalho, A. C. Rocha, T. L. Seus, R. Raiol, F. B. Del Vecchio, and V. S. Coswig, "Addition of Blood Flow Restriction to Passive Mobilization Reduces the Rate of Muscle Wasting in Elderly Patients in the Intensive Care Unit: A Within-Patient Randomized Trial," *Clinical Rehabilitation* 33 (2019): 233–240.

31. N. Beyer, I. Bautmans, R. Njemini, C. Demanet, P. Bergmann, and T. Mets, "Effects of Muscle Performance of NSAID Treatment With Piroxicam Versus Placebo in Geriatric Patients With Acute Infection-Induced Inflammation. A Double-Blind Randomized Controlled Trial," *BMC Musculoskeletal Disorders*. 12 (2011): 12.

32. A. C. Bodilsen, M. M. Pedersen, J. Petersen, et al., "Acute Hospitalization of the Older Patient: Changes in Muscle Strength and Functional Performance During Hospitalization and 30 Days After Discharge," *American Journal of Physical Medicine & Rehabilitation* 92 (2013): 789–796.

33. C. Bologna and E. Pone, "Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association With Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients With COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit," *Healthcare (Basel)* 10, no. 1 (2022): 162.

34. D. L. Borges, M. G. Silva, L. N. Silva, et al., "Effects of Aerobic Exercise Applied Early After Coronary Artery Bypass Grafting on Pulmonary Function, Respiratory Muscle Strength, and Functional Capacity: A Randomized Controlled Trial," *Journal of Physical Activity & Health* 13 (2016): 946–951.

35. J. M. Bradford, T. C. P. Cardenas, S. Lara, et al., "The More You Have, the More You Lose: Muscle Mass Changes in Trauma Patients With Prolonged Hospitalizations," *Injury* 54 (2023): 1102–1105.

36. K. A. Butera, A. M. Gustavson, J. E. Forster, D. Malone, and J. E. Stevens-Lapsley, "Admission Cognition and Function Predict Change in Physical Function Following Skilled Nursing Rehabilitation," *Journal of the American Medical Directors Association* 25 (2024): 17–23.

37. L. S. Chapple, M. J. Summers, L. M. Weinel, et al., "Muscle Size, Strength, and Physical Function in Response to Augmented Calorie Delivery: A TARGET Sub-Study," *Journal of Critical Care.* 72 (2022): 154140.

38. V. S. Chites, P. P. Teixeira, J. Lima, C. F. Burgel, T. Gattermann Pereira, and F. M. Silva, "Reduced Handgrip Strength in Hospital Admission Predicts Prolonged Hospital Stay and Death but Is Not Accurate to Identify Malnutrition: A Longitudinal Study of Reduced Handgrip Strength in Hospitalized Patients," *JPEN Journal of Parenteral and Enteral Nutrition* 45 (2021): 1016–1022.

39. M. M. M. da Silva, C. F. Travensolo, V. S. Probst, and J. M. Felcar, "Quantification of Changes in Functional Capacity and Muscle Strength in Patients: A Burn Intensive Care Unit Cohort Study," *Burns* 48 (2022): 833–840. 40. M. C. de Andrade-Junior, I. C. D. de Salles, C. M. M. de Brito, L. Pastore-Junior, R. F. Righetti, and W. P. Yamaguti, "Skeletal Muscle Wasting and Function Impairment in Intensive Care Patients With Severe COVID-19," *Frontiers in Physiology* 12 (2021): 640973.

41. S. L. De Buyser, M. Petrovic, Y. E. Taes, et al., "Functional Changes During Hospital Stay in Older Patients Admitted to an Acute Care Ward: A Multicenter Observational Study," *PLoS ONE* 9 (2014): e96398.

42. A.C.M. de Carvalho, C.S. Gomes, K. Menezes, et al., "Hospitalization Is Associated With Handgrip Strength Decline in Older Adults: A Longitudinal Study," *Aging Clinical and Experimental Research* 34 (2022): 619–624.

43. N. A. de Morton, J. L. Keating, D. J. Berlowitz, B. Jackson, and W. K. Lim, "Additional Exercise Does Not Change Hospital or Patient Outcomes in Older Medical Patients: A Controlled Clinical Trial," *Australian Journal of Physiotherapy* 53 (2007): 105–111.

44. P. H. de Moura, H. de Souza, D. C. Brandão, et al., "Mapping Peripheral and Abdominal Sarcopenia Acquired in the Acute Phase of COVID-19 During 7 Days of Mechanical Ventilation," *Scientific Reports* 13 (2023): 3514.

45. M. Dirks, D. Hansen, A. Van Assche, P. Dendale, and L. J. C. van Loon, "Neuromuscular Electrical Stimulation Prevents Muscle Wasting in Critically ill, Comatose Patients," *Clinical Science*. 128 (2015): 357–365.

46. M. M. Dusseaux, S. Antoun, S. Grigioni, et al., "Skeletal Muscle Mass and Adipose Tissue Alteration in Critically ill Patients," *PLoS ONE* 14 (2019): e0216991.

47. B. Eibel, J. R. Marques, T. Dipp, et al., "Ventilatory Muscle Training for Early Cardiac Rehabilitation Improved Functional Capacity and Modulated Vascular Function of Individuals Undergoing Coronary Artery Bypass Grafting: Pilot Randomized Clinical Trial," *International Journal of Environmental Research and Public Health* 19, no. 15 (2022): 9340.

48. K. Fränzel, J. Koschate, E. Freiberger, R. Shigematsu, T. Zieschang, and S. Tietgen, "Square-Stepping Exercise in Older Inpatients in Early Geriatric Rehabilitation. A Randomized Controlled Pilot Study," *BMC Geriatrics*. 24 (2024): 326.

49. V. Gerovasili, K. Stefanidis, K. Vitzilaios, et al., "Electrical Muscle Stimulation Preserves the Muscle Mass of Critically Ill Patients: A Randomized Study," *Critical Care* 13 (2009): R161.

50. L. M. Giangregorio, L. Thabane, J. Debeer, et al., "Body Weight-Supported Treadmill Training for Patients With hip Fracture: A Feasibility Study," *Archives of Physical Medicine and Rehabilitation* 90 (2009): 2125–2130.

51. S. Gil, G. N. de Oliveira Junior, F. M. Sarti, et al., "Acute Muscle Mass Loss Predicts Long-Term Fatigue, Myalgia, and Health Care Costs in COVID-19 Survivors," *Journal of the American Medical Directors Association* 24 (2023): 10–16.

52. P. Gualtieri, C. Falcone, L. Romano, et al., "Body Composition Findings by Computed Tomography in SARS-CoV-2 Patients: Increased Risk of Muscle Wasting in Obesity," *International Journal of Molecular Sciences* 21, no. 13 (2020): 4670.

53. V. Hadda, R. Kumar, G. C. Khilnani, et al., "Trends of Loss of Peripheral Muscle Thickness on Ultrasonography and Its Relationship With Outcomes Among Patients With Sepsis," *Journal of Intensive Care* 6 (2018): 81.

54. R. W. Haines, P. Zolfaghari, Y. Wan, R. M. Pearse, Z. Puthucheary, and J. R. Prowle, "Elevated Urea-To-Creatinine Ratio Provides a Biochemical Signature of Muscle Catabolism and Persistent Critical Illness After Major Trauma," *Intensive Care Medicine* 45 (2019): 1718–1731.

55. M. A. V. Hasanloei, M. Rahimlou, H. Shojaa, N. Morshedzadeh, R. Tavasolian, and R. Hashemi, "The Effect of Wheat Germ-Enriched

Enteral Formula on Clinical and Anthropometric Factors in Mechanically Ventilated Patients Admitted to the Intensive Care Unit," *Clinical Nutrition ESPEN* 46 (2021a): 40–46.

56. M. A. V. Hasanloei, A. Zeinaly, M. Rahimlou, H. Houshyar, S. Moonesirad, and R. Hashemi, "Effect of Coenzyme Q10 Supplementation on Oxidative Stress and Clinical Outcomes in Patients With Low Levels of Coenzyme Q10 Admitted to the Intensive Care Unit," *Journal of Nutritional Science* 10 (2021b): e48.

57. K. Hayes, A. E. Holland, V. A. Pellegrino, S. Mathur, and C. L. Hodgson, "Acute Skeletal Muscle Wasting and Relation to Physical Function in Patients Requiring Extracorporeal Membrane Oxygenation (ECMO)," *Journal of Critical Care* 48 (2018): 1–8.

58. M. Hickson, C. Bulpitt, M. Nunes, et al., "Does Additional Feeding Support Provided by Health Care Assistants Improve Nutritional Status and Outcome in Acutely ill Older in-Patients?—A Randomised Control Trial," *Clinical Nutrition* 23 (2004): 69–77.

59. F. W. Hu, Y. T. Huang, H. S. Lin, C. H. Chen, M. J. Chen, and C. M. Chang, "Effectiveness of a Simplified Reablement Program to Minimize Functional Decline in Hospitalized Older Patients," *Geriatrics & Gerontology International* 20 (2020): 436–442.

60. C. T. Jones, A. J. Lowe, L. MacGregor, C. A. Brand, N. Tweddle, and D. M. Russell, "A Randomised Controlled Trial of an Exercise Intervention to Reduce Functional Decline and Health Service Utilisation in the Hospitalised Elderly," *Australasian Journal on Ageing.* 25 (2006): 126–133.

61. M. Kangalgil, H. Ulusoy, S. Turan, and K. Oncu, "Association Between Skeletal Muscle Changes, Anthropometric Measurements, and Clinical Outcomes in Critically Ill Trauma and Surgical Patients: A Prospective Observational Study," *Nutrition in Clinical Practice* 37 (2022): 1326–1335.

62. M. Kangalgil, A. O. Küçük, H. Ulusoy, and A. Özçelik, "Nutrition Determinants of Acute Skeletal Muscle Loss in Critically Ill Patients: A Prospective Observational Cohort Study," *Nutrition in Clinical Practice* 39 (2024): 579–588.

63. A. Karlsen, M. R. Loeb, K. B. Andersen, et al., "Improved Functional Performance in Geriatric Patients During Hospital Stay," *American Journal of Physical Medicine & Rehabilitation* 96 (2017): e78–e84.

64. Y. Katari, R. Srinivasan, P. Arvind, and S. Hiremathada, "Point-Of-Care Ultrasound to Evaluate Thickness of Rectus Femoris, Vastus Intermedius Muscle, and Fat as an Indicator of Muscle and Fat Wasting in Critically Ill Patients in a Multidisciplinary Intensive Care Unit," *Indian Journal of Critical Care Medicine* 22 (2018): 781–788.

65. C. H. Kim, J. Han, and J. W. Kim, "One-Year Change in Handgrip Strength in Patients With Hip Fracture: A Prospective Comparison With Hip Disease," *BMC Geriatrics* 23 (2023): 65.

66. I. W. K. Kouw, B. B. L. Groen, J. S. J. Smeets, et al., "One Week of Hospitalization Following Elective Hip Surgery Induces Substantial Muscle Atrophy in Older Patients," *Journal of the American Medical Directors Association* 20 (2019): 35–42.

67. L. Kronborg, T. Bandholm, H. Palm, H. Kehlet, and M. T. Kristensen, "Effectiveness of Acute in-Hospital Physiotherapy With Knee-Extension Strength Training in Reducing Strength Deficits in Patients With a Hip Fracture: A Randomised Controlled Trial," *PLoS ONE* 12 (2017): e0179867.

68. E. López Jiménez, M. Neira Álvarez, R. Menéndez Colino, et al., "Muscle Mass Loss Measured With Portable Ultrasound in Hospitalized Older Adults: The ECOSARC Study," *Journal of Nutrition, Health & Aging* 28 (2024): 100010.

69. A. Martín-Salvador, I. Torres-Sánchez, G. Sáez-Roca, I. López-Torres, E. Rodríguez-Alzueta, and C. M. Valenza, "Age Group Analysis of Psychological, Physical and Functional Deterioration in Patients Hospitalized for Pneumonia," *Archivos de Bronconeumologia*. 51 (2015): 496–501. 70. N. Martinez-Velilla, A. Casas-Herrero, F. Zambom-Ferraresi, et al., "Effect of Exercise Intervention on Functional Decline in Very Elderly Patients During Acute Hospitalization: A Randomized Clinical Trial. JAMA," *Internal Medicine* 179 (2019): 28–36.

71. A. M. Martone, L. Bianchi, P. Abete, et al., "The Incidence of Sarcopenia Among Hospitalized Older Patients: Results From the Glisten Study," *Journal of Cachexia, Sarcopenia and Muscle* 8 (2017): 907–914.

72. K. P. Mayer, M. L. Thompson Bastin, A. A. Montgomery-Yates, et al., "Acute Skeletal Muscle Wasting and Dysfunction Predict Physical Disability at Hospital Discharge in Patients With Critical Illness," *Critical Care* 24 (2020): 637.

73. A. S. McNelly, D. E. Bear, B. A. Connolly, et al., "Effect of Intermittent or Continuous Feed on Muscle Wasting in Critical Illness: A Phase 2 Clinical Trial," *Chest* 158 (2020): 183–194.

74. T. Mets, I. Bautmans, R. Njemini, M. Lambert, and C. Demanet, "The Influence of Celecoxib on Muscle Fatigue Resistance and Mobility in Elderly Patients With Inflammation," *American Journal of Geriatric Pharmacotherapy*. 2 (2004): 230–238.

75. N. Mgbemena, A. Jones, P. Saxena, N. Ang, S. Senthuran, and A. Leicht, "Acute Changes in Handgrip Strength, Lung Function and Health-Related Quality of Life Following Cardiac Surgery," *PLoS ONE* 17 (2022): e0263683.

76. N. Nakanishi, J. Oto, R. Tsutsumi, Y. Akimoto, Y. Nakano, and M. Nishimura, "Upper Limb Muscle Atrophy Associated With in-Hospital Mortality and Physical Function Impairments in Mechanically Ventilated Critically ill Adults: A Two-Center Prospective Observational Study," *Journal of Intensive Care* 8 (2020): 87.

77. F. P. Nery, A. J. Lopes, D. N. Domingos, et al., "CPAP Increases 6-Minute Walk Distance After Lung Resection Surgery," *Respiratory Care* 57 (2012): 363–369.

78. R. P. M. Neto, L. M. B. Esposito, F. C. da Rocha, et al., "Photobiomodulation Therapy (Red/NIR LEDs) Reduced the Length of Stay in Intensive Care Unit and Improved Muscle Function: A Randomized, Triple-Blind, and Sham-Controlled Trial," *Journal of Biophotonics* 17 (2024): e202300501.

79. M. R. Nickels, L. M. Aitken, A. G. Barnett, et al., "Effect of in-Bed Cycling on Acute Muscle Wasting in Critically Ill Adults: A Randomised Clinical Trial," *Journal of Critical Care* 59 (2020): 86–93.

80. K. L. Norheim, I. Bautmans, and M. Kjaer, "Handgrip Strength Shows No Improvements in Geriatric Patients With Persistent Inflammation During Hospitalization," *Experimental Gerontology* 99 (2017): 115–119.

81. T. Ogasawara, S. Marui, E. Miura, et al., "Effect of Eicosapentaenoic Acid on Prevention of Lean Body Mass Depletion in Patients With Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Randomized Controlled Trial," *Clinical Nutrition (ESPEN).* 28 (2018): 67–73.

82. J. Ortiz-Alonso, N. Bustamante-Ara, P. L. Valenzuela, et al., "Effect of a Simple Exercise Programme on Hospitalisation-Associated Disability in Older Patients: A Randomised Controlled Trial," *Journal of the American Medical Directors Association*. 21 (2019): 531–537.

83. S. M. Parry, D. El-Ansary, M. S. Cartwright, et al., "Ultrasonography in the Intensive Care Setting Can Be Used to Detect Changes in the Quality and Quantity of Muscle and Is Related to Muscle Strength and Function," *Journal of Critical Care* 30, no. 1151 (2015): e9–e14.

84. F. Pitta, T. Troosters, V. S. Probst, M. A. Spruit, M. Decramer, and R. Gosselink, "Physical Activity and Hospitalization for Exacerbation of COPD," *Chest* 129 (2006): 536–544.

85. M. Pourhassan, N. Rommersbach, G. Lueg, et al., "The Impact of Malnutrition on Acute Muscle Wasting in Frail Older Hospitalized Patients," *Nutrients* 12, no. 5 (2020): 1387.

86. Z. A. Puthucheary, J. Rawal, M. McPhail, et al., "Acute Skeletal Muscle Wasting in Critical Illness," *Journal of the American Medical Association* 310 (2013): 1591–1600.

87. K. A. Ramsey, A. G. M. Rojer, E. van Garderen, et al., "The Association of Changes in Physical Performance During Geriatric Inpatient Rehabilitation With Short-Term Hospital Readmission, Institutionalization, and Mortality: RESORT," *JAMDA*. 23 (2022): e1–e8.

88. M. J. Raymond, K. J. Jeffs, A. Winter, S. E. Soh, P. Hunter, and A. E. Holland, "The Effects of a High-Intensity Functional Exercise Group on Clinical Outcomes in Hospitalised Older Adults: An Assessor-Blinded, Randomised-Controlled Trial," *Age and Ageing* 46 (2017): 208–213.

89. C. N. Rodrigues, J. Ribeiro Henrique, A. R. S. Ferreira, and M. Correia, "Ultrasonography and Other Nutrition Assessment Methods to Monitor the Nutrition Status of Critically Ill Patients," *JPEN Journal of Parenteral and Enteral Nutrition* 45 (2021): 982–990.

90. E. Segaran, L. Wandrag, M. Stotz, M. Terblanche, and M. Hickson, "Does Body Mass Index Impact on Muscle Wasting and Recovery Following Critical Illness? A Pilot Feasibility Observational Study," *Journal of Human Nutrition and Dietetics* 30 (2017): 227–235.

91. J. Segers, I. Vanhorebeek, D. Langer, et al., "Early Neuromuscular Electrical Stimulation Reduces the Loss of Muscle Mass in Critically ill Patients—A Within Subject Randomized Controlled Trial," *Journal of Critical Care* 62 (2021): 65–71.

92. P. E. Silva, M. R. de Cassia, K. Livino-de-Carvalho, et al., "Neuromuscular Electrical Stimulation in Critically III Traumatic Brain Injury Patients Attenuates Muscle Atrophy, Neurophysiological Disorders, and Weakness: A Randomized Controlled Trial," *Journal of Intensive Care* 7 (2019): 59.

93. B. Strasser, V. Grote, W. Bily, et al., "Short-Term Effects of Dietary Protein Supplementation on Physical Recovery in Older Patients at Risk of Malnutrition During Inpatient Rehabilitation: A Pilot, Randomized, Controlled Trial," *Healthcare (Basel)* 11, no. 6 (2023): 2317.

94. S. Tazerout, O. Martinez, B. Monsonis, et al., "Acute Post-Traumatic Muscle Atrophy on CT Scan Predicts Prolonged Mechanical Ventilation and a Worse Outcome in Severe Trauma Patients," *Injury* 53 (2022): 2501–2510.

95. F. Temporiti, A. Ruspi, D. De Leo, et al., "Action Observation and Motor Imagery Administered the Day Before Surgery Enhance Functional Recovery in Patients After Total Hip Arthroplasty: A Randomized Controlled Trial," *Clinical Rehabilitation* 36 (2022): 1613–1622.

96. D. O. Toledo, B. J. de Freitas, R. Dib, et al., "Peripheral Muscular Ultrasound as Outcome Assessment Tool in Critically Ill Patients on Mechanical Ventilation: An Observational Cohort Study," *Clinical Nutrition (ESPEN).* 43 (2021): 408–414.

97. I. Torres-Sanchez, M. C. Valenza, I. Cabrera-Martos, I. Lopez-Torres, A. Benitez-Feliponi, and A. Conde-Valero, "Effects of an Exercise Intervention in Frail Older Patients With Chronic Obstructive Pulmonary Disease Hospitalized due to an Exacerbation: A Randomized Controlled Trial," *COPD* 14 (2017): 37–42.

98. T. N. Trung, N. V. T. Duoc, L. T. H. Nhat, et al., "Functional Outcome and Muscle Wasting in Adults With Tetanus," *Transactions of the Royal Society of Tropical Medicine and Hygiene* 113 (2019): 706–713.

99. P. Turton, R. Hay, J. Taylor, J. McPhee, and I. Welters, "Human Limb Skeletal Muscle Wasting and Architectural Remodeling During Five to Ten Days Intubation and Ventilation in Critical Care—An Observational Study Using Ultrasound," *BMC Anesthesiology* 16 (2016): 119.

100. A. C. Verceles, M. Serra, D. Davis, et al., "Combining Exercise, Protein Supplementation and Electric Stimulation to Mitigate Muscle Wasting and Improve Outcomes for Survivors of Critical Illness—The ExPrES Study," *Heart & Lung.* 58 (2023): 229–235.

101. M. A. P. Vermeeren, E. F. M. Wouters, A. J. W. Geraerts-Keeris, and A. M. W. J. Schols, "Nutritional Support in Patients With Chronic Obstructive Pulmonary Disease During Hospitalization for an Acute Exacerbation; a Randomized Controlled Feasibility Trial," *Clinical Nutrition* 23 (2004): 1184–1192.

102. C. Welch, C. Greig, D. Lewis, et al., "Trajectories of Muscle Quantity, Quality and Function Measurements in Hospitalized Older Adults," *Geriatrics & Gerontology International* 22 (2022a): 311–318.

103. C. Welch, C. Greig, Z. Majid, et al., "Induced Frailty and Acute Sarcopenia Are Overlapping Consequences of Hospitalisation in Older Adults," *Journal of Frailty, Sarcopenia and Falls* 7 (2022b): 103–116.

104. C. Werner, L. Bauknecht, P. Heldmann, et al., "Mobility Outcomes and Associated Factors of Acute Geriatric Care in Hospitalized Older Patients: Results From the PAGER Study," *European Geriatric Medicine* 15 (2024): 139–152.

105. B. R. Wnuk, J. Durmala, K. Ziaja, P. Kotyla, M. Wozniewski, and E. Blaszczak, "A Controlled Trial of the Efficacy of a Training Walking Program in Patients Recovering From Abdominal Aortic Aneurysm Surgery," *Advances in Clinical and Experimental Medicine* 25 (2016): 1241–1371.

106. T. T. Wu, Q. L. Chen, X. X. Lin, et al., "Effects of a Multilevel Intervention of Resistance Training With or Without Beta-Hydroxy-Beta-Methylbutyrate in Medical ICU Patients During Entire Hospitalisation: A Four-Arm Multicentre Randomised Controlled Trial," *Critical Care (London, England)* 27 (2023): 27.

107. Y. Xie, S. Liu, H. Zheng, L. Cao, K. Liu, and X. Li, "Utility of Plasma GDF-15 for Diagnosis and Prognosis Assessment of ICU-Acquired Weakness in Mechanically Ventilated Patients: Prospective Observational Study," *BioMed Research International* 2020 (2020): 3630568–9.

108. W. Xue, Z. Xinlan, and Z. Xiaoyan, "Effectiveness of Early Cardiac Rehabilitation in Patients With Heart Valve Surgery: A Randomized, Controlled Trial," *Journal of International Medical Research*. 50 (2022): 3000605211044320.

109. A. J. Cruz-Jentoft, J. P. Baeyens, J. M. Bauer, et al., "Sarcopenia: European Consensus on Definition and Diagnosis: Report of the European Working Group on Sarcopenia in Older People," *Age and Ageing* 39 (2010): 412–423.

110. C. Sohrabi, G. Mathew, T. Franchi, et al., "Impact of the Coronavirus (COVID-19) Pandemic on Scientific Research and Implications for Clinical Academic Training—A Review," *International Journal of Surgery* 86 (2021): 57–63.

111. M. Mourtzakis, C. M. Prado, J. R. Lieffers, T. Reiman, L. J. McCargar, and V. E. Baracos, "A Practical and Precise Approach to Quantification of Body Composition in Cancer Patients Using Computed Tomography Images Acquired During Routine Care," *Applied Physiology, Nutrition, and Metabolism* 33 (2008): 997–1006.

112. J. M. Van Ancum, J. Alcazar, C. G. M. Meskers, B. R. Nielsen, C. Suetta, and A. B. Maier, "Impact of Using the Updated EWGSOP2 Definition in Diagnosing Sarcopenia: A Clinical Perspective," *Archives* of Gerontology and Geriatrics 90 (2020): 104125.

113. A. K. Stuck, L. T. Tsai, G. Freystaetter, et al., "Comparing Prevalence of Sarcopenia Using Twelve Sarcopenia Definitions in a Large Multinational European Population of Community-Dwelling Older Adults," *Journal of Nutrition, Health & Aging* 27 (2023): 205–212.

114. P. J. Lim, S. Yew, L. Tay, et al., "Grip Strength Criterion Matters: Impact of Average Versus Maximum Handgrip Strength on Sarcopenia Prevalence and Predictive Validity for Low Physical Performance," *Journal of Nutrition, Health & Ageing.* 24 (2020): 1031–1035.

115. M. R. de Almeida, V. F. de Souza, T. C. do Rosario, et al., "Agreement Between Maximum and Mean Handgrip Strength Measurements in Cancer Patients," *PLoS ONE* 17 (2022): e0270631.

116. S. Volpato, M. Cavalieri, F. Sioulis, et al., "Predictive Value of the Short Physical Performance Battery Following Hospitalization in Older Patients," *Journals of Gerontology. Series a, Biological Sciences and Medical Sciences* 66 (2011): 89–96.

117. W. G. Looijaard, I. M. Dekker, S. N. Stapel, et al., "Skeletal Muscle Quality as Assessed by CT-Derived Skeletal Muscle Density Is Associated With 6-Month Mortality in Mechanically Ventilated Critically Ill Patients," *Critical Care* 20 (2016): 386.

118. L. van Wijk, S. van Duinhoven, M. S. L. Liem, D. E. Bouman, A. R. Viddeleer, and J. M. Klaase, "Risk Factors for Surgery-Related Muscle Quantity and Muscle Quality Loss and Their Impact on Outcome," *European Journal of Medical Research* 26 (2021): 36.

119. C. Beaudart, M. Zaaria, F. Pasleau, J. Y. Reginster, and O. Bruyere, "Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis," *PLoS ONE* 12 (2017): e0169548.

#### **Supporting Information**

Additional supporting information can be found online in the Supporting Information section.